Why Was The Word-Wide Vaccine industry So Panicked Over The Geiers Addressing the UNEP Meeting in Japan? May 25, 2011

Virtually all licensed vaccines in the United States are produced by just a handful of pharmaceutical companies: GlaxoSmithKline, Merck, Novartis, Sanofi Pasteur, and Wyeth. These companies account for 80 percent of the worldwide vaccine market.

With a limited number of manufacturers and many recommended vaccines produced by only a single company, vaccines are susceptible to large fluctuations in supply and availability.

Thirty years ago, the vaccine market looked remarkably different. At the time, 35 companies produced vaccines for use in the United States, and similar departures from the international vaccine market have also occurred in the intervening years. Between 1988 and 2001, 10 of 14 global vaccine manufactures partially or completely stopped production of traditional childhood vaccines.

Health policy experts and economists attribute this trend primarily to market and financial considerations–namely, sparse profits; costly research, development and production; and liability concerns.” They go on to say several other important things, explaining how the vaccine industry works. In short, the industry is completely dependant on government protection from lawsuits. More, governments are the biggest buyers of vaccines. VaccineEthics.org says: “Meanwhile, the largest single purchasers of vaccines are governments. In the U.S., for example, the federal and state branches constitute close to 60 percent of all pediatric vaccines sold in the country.

” This financial landscape means that the vaccine industry is unlikely to invest in a product that will not both pay for itself and turn a profit–characteristics which (almost) require a significant demand in wealthy, developed countries…. Since it is estimated 60 percent of vaccine production costs are fixed, meaning they are incurred regardless of the amount of product produced, vaccines require a sizable market to be profitable.”